Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy

Kademani, Deepak; Koka, Sreenivas; Lacy, Martha Q.; Rajkumar, S. Vincent
August 2006
Mayo Clinic Proceedings;Aug2006, Vol. 81 Issue 8, p1100
Academic Journal
Bisphosphonate chemotherapy is commonly used In the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has Improved the quality of life In a vast majority of patients, showing clear medical efficacy. However, since 2003 a growing number of reports have described necrotic bone lesions (osteonecrosis of the jaw [ONJ]) affecting maxillofacial bones in patients who have received chemotherapy with intravenous bisphosphonate therapy. Unfortunately, the development of ONJ has been refractory to conventional treatment modalities. Several treatment options have been proposed for ONJ, most of which focus primarily on conservative management with local irrigation and empirical long-term antibiotic therapy. However, results of treatment have been associated with high failure rates, progression of disease, and continued decline in patients' quality of life. We describe 2 patients in whom primary surgical salvage was performed successfully for ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with ONJ.


Related Articles

  • Osteonecrosis of the jaw associated with antiresorptives: more evidence on the role of infection. Pazianas, Michael // IBMS BoneKEy;Nov2013, Vol. 10 Issue 11, p441 

    The author comments on the study conducted by S. Kalyan and colleagues which examines the role of infection in the initiation of osteonecrosis of the jaw (ONJ) associated with antiresorptives. He says that the significance of this study on the unaffected part of monocytes in patients treated...

  • Ostéonécrose des maxillaires : quand l'ancien traitement avec bisphosphonates est méconnu. Renoux, Marion; Folliguet, Marysette; Nguyen, Thông; Radoï, Loredana // Médecine Buccale Chirurgie Buccale;2014, Vol. 20 Issue 3, p177 

    Introduction: Older people have multiple morbidities and are polymedicated. The medicines are prescribed by several doctors who are unaware of each other, hence the increased risk of adverse effects. Observation: We report the case of an institutionalized 91-year-old female patient. Following a...

  • Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Bobba, Raja S.; Beattie, Karen; Parkinson, Bill; Kumbhare, Dinesh; Adachi, Jonathan D. // Drug Safety;2006, Vol. 29 Issue 12, p1133 

    Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of...

  • Bisphosphonates.  // Reactions Weekly;3/26/2011, Issue 1344, p10 

    The article describes the cases of two men and 25 women aged 62 to 85 years who developed osteonecrosis of the jaw (ONJ) while receiving biphosphonates, including alendronic acid, ibandronic acid and pamidronic acid.

  • Bisphosphonates.  // Reactions Weekly;03/23/2013, Issue 1445, p12 

    The article presents a case study of the development of osteonecrosis of the jaw in four men and sixteen women, aged 48-84 years while receiving bisphosphonates.

  • Zoledronic acid.  // Reactions Weekly;4/24/2010, Issue 1298, p31 

    The article describes the case of a 47-year-old man who developed osteonecrosis of the jaw (ONJ) while receiving zoledronic acid.

  • Pamidronic acid/zoledronic acid.  // Reactions Weekly;3/13/2010, Issue 1292, p28 

    The article describes the case of two patients who acquired osteonecrosis of the jaw (ONJ) following administration of biphosphonates, pamidonic acid or zoledronic acid.

  • Zoledronic Acid. Cheer, S.M.; Noble, S. // Drugs;Apr2001, Vol. 61 Issue 6, p799 

    â–´ Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D-induced hypercalcaemia in a rat model and calcium release in vitro. â–´ A single...

  • Osteoporosis medications and oral health.  // Journal of the American Dental Association (JADA);Jun2009, Vol. 140 Issue 6, p812 

    The article focuses on osteoporosis medications and oral health of older people in the U.S. Osteoporosis which affects the quality of life of patients, is a condition in which bones become weak and prone to break due of various factors like diet, physical activity and medications like...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics